Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
NVCT
NVCT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NVCT News
Multiple Companies Show Strong Stock Performance
13h ago
NASDAQ.COM
Nuvectis Pharma to Present at BioConnect Investor Conference
May 14 2026
Newsfilter
Nuvectis Pharma Reports Q1 2026 Financial Results and NXP900 Update
May 05 2026
Newsfilter
NUVECTIS PHARMA, INC. ANNOUNCES FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR FIRST QUARTER 2026
May 05 2026
moomoo
Nuvectis Pharma Reports FY GAAP EPS of -$1.32
Feb 11 2026
seekingalpha
Nuvectis Pharma Reports 2025 Financial Results and Business Progress
Feb 11 2026
Newsfilter
Nuvectis Initiates Phase 1b Study of NXP900 with Osimertinib for EGFRmut+NSCLC
Dec 17 2025
Globenewswire
Nuvectis Initiates Phase 1b Study of NXP900 with Osimertinib for EGFRmut+NSCLC
Dec 17 2025
Newsfilter
Nuvectis Pharma, Inc. Announces Financial Results and Business Highlights for Q3 2025
Nov 04 2025
Newsfilter
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights
Aug 05 2025
Newsfilter
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
Jul 31 2025
Newsfilter
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting
Apr 29 2025
Newsfilter
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting
Mar 26 2025
Newsfilter
Laidlaw & Co. Initiates Coverage On Nuvectis Pharma with Buy Rating, Announces Price Target of $19
Mar 17 2025
Benzinga
Nuvectis Pharma initiated with a Buy at Laidlaw
Mar 17 2025
Business Insider
Nuvectis Pharma to Participate in the 37th Annual Roth Conference
Mar 14 2025
Newsfilter
Show More News
